RECORDATI : REVENUE GROWTH AND SIGNIFICAT MARGIN

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
RECORDATI : REVENUE GROWTH AND SIGNIFICAT MARGIN IMPROVEMENT IN FIRST NINE MONTHS 2014 RESULTS.
  • Consolidated revenue € 742.1 million, + 5.7%.
  • EBITDA (1) € 212.9 million, + 22.4%
  • Operating income € 180.4 million, + 21.6%.
  • Net income € 124.0 million, + 22.2%.
  • Net financial position (2) :  net debt of € 152.5 million.
  • Vitaros®, an innovative product for the treatment of erectile dysfunction licensed in from Apricus Biosciences.
  • Acquisition of a further 23% of the share capital of Opalia Pharma S.A. in Tunisia.
  • Orphan drug designation granted to Carbaglu® for the treatment of organic acidemias in the U.S.A..
  • PSD502(TM), a n ew product for the treatment of premature ejaculation licensed in from Plethora Solutions.
  • Full year 2014 targets improved.
  • Interim 2014 dividend of € 0.26 per share to be distributed.

MILANO, Italy, Oct. 28, 2014 (GLOBE NEWSWIRE) -- The Board of Directors of Recordati S.p.A. approved the Group's consolidated results for the first nine months 2014 prepared in accordance with International Accounting Standards and International Financial Reporting Standards (IAS/IFRS) and in particular as per IAS 34 requirements for interim reporting. These financial statements will be available today at the company's offices and on the company's website:
http://www.recordati.com/rec_en/investors/reports/ and can also be viewed on the authorized storage system 1Info ( www.1Info.it ).

Financial highlights

  • Consolidated revenue in the first nine months 2014 is € 742.1 million, up by 5.7% compared to the same period of the preceding year. International sales grow by 8.1%.
     
  • EBITDA (1) , at 28.7% of sales, is € 212.9 million, an increase of 22.4% over the same period of the preceding year.
     
  • Operating income , at 24.3% of sales, is € 180.4 million, an increase of 21.6%.
     
  • Net income, at 16.7% of sales, is € 124.0 million, an increase of 22.2% over the first nine months of 2013.
     
  • Net financial position (2) at 30 September 2014 records a net debt of € 152.5 million. Shareholders' equity increases to € 819.4 million.

             
(1) Earnings before interest, taxes, depreciation and amortization.
(2) Cash and short-term financial investments less bank overdrafts and medium/long-term loans which include the measurement at fair value of hedging derivatives (fair value hedge).

Business development news

In February an exclusive license agreement was entered into with Apricus Biosciences Inc., a pharmaceutical company based in San Diego, U.S.A., for the marketing and sales of Vitaros® (alprostadil), an innovative topical product for the treatment of erectile dysfunction, in certain W. European countries including, among others, Spain, EU member countries in Central and Eastern Europe, Russia, Ukraine and the Commonwealth of Independent States (C.I.S.), Turkey and certain African countries. Vitaros ® is approved for the treatment of erectile dysfunction by a number of European health authorities and by Health Canada.  Vitaros ® is a topically-applied cream formulation of alprostadil, a vasodilator, which directly increases blood flow to the penis, causing an erection. Alprostadil is an alternative to the PDE-5 inhibitors for difficult to treat patients and Vitaros ® offers a patient-friendly form versus other alprostadil dosage forms.

In May the acquisition of a further 23% of the share capital of Opalia Pharma S.A., a Tunisian pharmaceutical company with headquarters in Ariana, near Tunis, was successfully concluded. This second tranche consists of share capital held by Tunisian shareholders. In October 2013, following permission received from the Tunisian anti-trust authorities, 67% of the share capital of Opalia Pharma S.A. held by non-Tunisian shareholders was acquired. An amount of € 22.6 million were paid at the closing. In May 2014, following permission granted by the Commission Supérieure des Investissements in Tunisia, a further 23% of the share capital of Opalia Pharma S.A. was acquired. The price of this portion of shares is of around € 5.9 million of which € 4.3 million already paid. Consequently, as of today Recordati holds 90% of the share capital of Opalia Pharma S.A., while the remaining 10% is held by Mrs. Alya El Hedda, one of the founders of Opalia Pharma S.A. and current General Manager of the company.

In July the U.S. Food and Drug Administration (FDA) granted approval of Orphan Europe's request for orphan drug designation for the use of Carbaglu® (carglumic acid) in the treatment of organic acidemias (OAs). Orphan drug designation applies to drugs that seek to treat rare diseases or conditions affecting fewer than 200,000 patients in the U.S. while providing significant therapeutic advantage over existing therapies. The designation provides the opportunity for seven years marketing exclusivity upon approval for the designated indication, tax credits to offset clinical research expenses, the ability to apply for annual grant funding, and the potential waiver of prescription drug user fees.

In September a license agreement with Plethora Solutions Limited and Plethora Solutions Holdings Plc, a specialty pharmaceutical company with headquarters in the UK, for the commercialization of PSD502(TM) in Europe, Russia, Commonwealth of Independent States (C.I.S.), Turkey and certain countries in North Africa was signed. Subsequently, during October an up-front payment of € 5 million to Plethora was effected. PSD502(TM) is an easy-to-use fast acting topical spray formulation of lidocaine and prilocaine for the treatment of premature ejaculation. Premature ejaculation is a common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20% to 30% in men of all ages. The product has been approved by EMA (the European Medicines Agency) but the new dosage form which will be actually commercialized is currently in development and will require a variation of the approval.

At the end of September Erytech Pharma, a French biopharmaceutical company with which Orphan Europe, Recordati group, established an exclusive agreement in 2012 for the commercialization and distribution in Europe of Graspa® (a treatment for hematological malignancies intended to satisfy the unmet medical needs of frail patients, patients suffering relapses and other patient groups for whom the current treatments are not suitable) reported positive top-line phase III results from its clinical study with Graspa® in acute lymphoblastic leukemia (ALL). Graspa® met the primary endpoints compared to native L-asparaginase: the reduction of allergic reactions was statistically significant and the increase in duration of asparaginase activity was also statistically significant.

Business outlook

The group's business performance was in line with expectations during October. For the full year 2014, in view of the results obtained in the first nine months of the year, targets are to achieve sales of slightly below € 1,000 million, operating income of around € 230 million and net income of around € 160 million.

Further resolutions

2014 Interim dividend

The Board of Directors resolved to distribute an interim dividend relating to the financial year 2014 amounting to € 0.26 (before withholding tax) on each outstanding share, excluding shares in treasury stock. The interim dividend will be paid, through the authorised intermediaries, as from November 19, 2014 (record date November 18, 2014) on coupon No. 14 to be presented on November 17, 2014.

The Independent Auditor's opinion on the distribution of the interim dividend is also available at the Company's registered offices as per article 2433-bis of the Italian Civil Code.

The Directors' Report and financial statements of Recordati S.p.A. as at 30 June 2014, on which the Board of Directors based its resolution to distribute the abovementioned interim dividend, are available at the Company's registered offices and published on the Company's website ( www.recordati.com ). Such documents can also be viewed on the authorized storage system 1Info ( www.1Info.it ).

Conference call

Recordati will be hosting a conference call today 28 October 2014 at 4.00 pm Italian time (3.00 pm London time, 9.00 am New York time). The dial-in numbers are:

Italy                             +39 02 8058811, toll free 800 213 858
UK                                +44 1 212818003, toll free 800 0156384
USA                             +1 718 7058794, toll free 855 2656959
France                        +33 170918703
Germany                   +49 65 255114451

Callers are invited to dial-in 10 minutes before conference time.  If conference operator assistance is required during the connection please digit * followed by 0 or call +39 02 8061371.  A recording of the conference call will be placed on the website www.recordati.com .

A set of slides which will be referred to during the call will be available on our website www.recordati.com under Investors/Company Presentations.

Recordati , established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America.  An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases.  Consolidated revenue for 2013 was € 941.6 million, operating income was € 195.4 million and net income was € 133.7 million.

For further information:

Recordati website:  www.recordati.com

Investor Relations                                                                       Media Relations                    
Marianne Tatschke                                                                     Studio Noris Morano                                                           
(39)0248787393                                                                          (39)0276004736, (39)0276004745
e-mail: inver@recordati.it                                                          e-mail: norismorano@studionorismorano.com
                                                                    

S tatements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI : REVENUE GROWTH AND SIGNIFICAT MARGIN IMPROVEMENT IN FIRST http://hugin.info/143644/R/1866311/655574.pdf

HUG#1866311

Scroll down for more posts ▼

Top 10 Most Recent News Articles

America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 38

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 301

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 83

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 139

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 164

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 24

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 131

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 155

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading

Top 5 Most Recently Viewed Articles

Lexicon Pharmaceuticals Unveils Q3 Financials and Future Plans

Updated Category News Views 138

Third Quarter Financial Highlights of Lexicon Pharmaceuticals Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has disclosed its financial performance for the third quarter of 2025, highlighting significant revenue increases attributed primarily to strategic licensing agreements and product sales. Strategic Partnerships and Revenue Growth In an impressive leap, Lexicon's...

Continue Reading
Growing Innovations in Robotic Dentistry to 2034 and Beyond

Updated Category News Views 178

The Rise of Robotic Dentistry and Its Market Growth The shift towards technological integration in the healthcare sector has begun a revolutionary transformation in dental care. The robotic dentistry market is anticipated to grow significantly, projected to increase from USD 617.39 million in 2024 to an approximate USD 2.24 billion by 2034. This acceleration is based on a...

Continue Reading
Chipotle Lawsuit Update: Key Actions for Shareholders

Updated Category News Views 126

Important Information for Chipotle Shareholders Shareholders of Chipotle Mexican Grill, Inc. (NYSE: CMG) are being advised about an ongoing class action lawsuit that could impact their investments. It is vital for all affected shareholders to take note of critical deadlines and actions they need to undertake to ensure their rights and potential recoveries are protected....

Continue Reading
Quisitive Technology Solutions Reports Q2 2024 Financial Results

Updated Category News Views 144

Quisitive Reports Second Quarter 2024 Financial Results Quisitive Technology Solutions Inc. (“Quisitive” or the “Company”) (TSXV: QUIS, OTCQX: QUISF), a leading provider of Microsoft Cloud and AI solutions, has announced its financial results for the second quarter ending June 30, 2024. Management Commentary Quisitive's CEO, Mike Reinhart, commented, “The first...

Continue Reading
Natural Grocers Reports Strong Fiscal 2024 Performance

Updated Category News Views 231

Natural Grocers by Vitamin Cottage Sees Remarkable Growth in Fiscal 2024 Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) has unveiled its financial results for the fourth quarter and full year of fiscal 2024. The report highlights significant sales and earnings achievements, showcasing the company’s robust performance in a competitive grocery market. Exceptional...

Continue Reading